Novo Nordisk revealed that weight loss pills are being closely monitored by the food industry, and executives from multiple companies are calling for consultation
阿豆学长长ov
发表于 2024-2-9 10:26:48
232
0
0
Recently, Lars Fruergaard Jorgensen, CEO of the Danish pharmaceutical group Novo Nordisk, revealed at an event in New York that several food company CEOs have been calling him to inquire about the efficacy and release speed of the "weight loss miracle drug".
Since last year, Semalutide, a subversive drug ingredient developed and produced by Novo Nordisk, has swept clinics in Europe and the United States. Wegovy, a weight loss drug with Semalutide as an effective ingredient, and Ozempic, a diabetes drug, have become household names.
It is understood that Smeglutide, a GLP-1 drug, can reduce blood sugar by simulating an intestinal hormone called GLP-1 and regulating patients' appetite to achieve the effect of treating type 2 diabetes and obesity. Meanwhile, scientists have discovered that drugs also have other functions such as treating kidney disease and inhibiting systemic inflammation.
Caixin News Agency previously mentioned that the popularity of Smegglutide may have potential impacts on industries such as food and beverage, medical devices, etc. Zhou Fude said that the degree of impact of drugs may vary by industry, for example, Vegway has already achieved significant clinical effects in treating weight related diseases such as kidney disease and knee osteoarthritis.
According to data from analysis agencies, by 2030, the size of the weight loss market alone may reach $80 billion. Wall Street research suggests that small changes in consumer behavior may have significant financial impacts. A few months ago, Wal Mart, the largest chain retailer in the United States, warned that some consumers had reduced their shopping demand after taking weight loss drugs.
In this regard, French company Danone, which has a yogurt business, believes that GLP-1 drugs will promote the development of the company's business, as people taking Smegglutide drugs will seek products with high protein and low fat content. Chipotle, a Mexican flavor chain restaurant in the United States, also stated that fresh food will still attract those who are trying to lose weight.
When asked if Unilever CEO Hein Schumacher had called Zhou Fude, he gave a negative answer. But Schumacher admits that the company is closely monitoring the situation, "you can't close your eyes to what's happening."
For some food producers who are considered unhealthy, Novo Nordisk's difficulty in quickly driving drug production may be good news. Zhou Fude pointed out that the company's acquisition of three production bases of Kangtai Lunte is the key to increasing production.
Earlier this week, Novo Holdings, the controlling shareholder of Novo Nordisk, announced that it will acquire Contilent in full cash for $11.5 billion, with Contilent's debt, resulting in a total transaction value of $16.5 billion. As part of the transaction, Novo Nordisk will acquire three production bases of Contilent from Novo Holdings for $11 billion.
Zhou Fude explained that in the long run, Novo Nordisk will be able to more effectively utilize the production capacity of Contilent to increase supply, thereby making its weight loss drugs benefit more people. He also mentioned, "The demand is much greater than the production capacity we can provide today."
He also pointed out that Lilly's entry into the market has a positive side for Novo Nordisk, "If they (Lilly) can persuade companies to include obesity drugs in insurance, the benefits the company actually receives will be higher than the drawbacks brought by competitive threats."
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- A key executive from Apple's Steve Jobs era is set to retire
- Jike executives respond to promotional video of eating hotpot in the car: to showcase the vehicle's fresh air system and new camping scenes
- Observation | Behind the marketing of Jike executives eating hotpot in their cars: When will car companies' "traffic anxiety disorder" stop
- BeiGene responds to investigation of company executives: the incident involving the employee has nothing to do with BeiGene
- 200 billion dollar pharmaceutical company officially responds to executive investigation
- A senior executive of BeiGene has been investigated, and insiders say that the reason for the investigation is unrelated to BeiGene
- Dingdong, which has seen a significant increase in net profit, is keeping a close eye on Jiangsu, Zhejiang, and Shanghai when buying groceries
- New developments in the detention of executives from multinational giants! AstraZeneca Global CEO Su Boke: Not familiar with any investigation details, currently limited information available
- JD's revenue growth accelerates in the third quarter, with executives revealing plans to increase investment in clothing and beauty
- AI revenue has grown for five consecutive quarters, and Alibaba executives say they look forward to user growth after integrating WeChat Pay
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏